Literature DB >> 16373652

Endovascular recanalization therapy in acute ischemic stroke.

Jae H Choi1, Brian T Bateman, Sundeep Mangla, Randolph S Marshall, Shyam Prabhakaran, Ji Chong, Jay P Mohr, Henning Mast, John Pile-Spellman.   

Abstract

BACKGROUND AND
PURPOSE: To assess the outcome in acute ischemic stroke patients not eligible for systemic thrombolysis (outside the 3-hour time window, after surgery, or on anticoagulant) undergoing endovascular recanalization therapy (ERT) at the Columbia University Medical Center (CUMC) and to determine US nationwide usage and outcome of ERT in acute ischemic stroke.
METHODS: Patients treated at CUMC from 2001 to 2004 and the Nationwide Inpatient Sample (NIS) comprising 20% of all admissions in the United States from 1999 to 2002 were analyzed retrospectively.
RESULTS: Thirty-one patients underwent ERT. Mean age was 68+/-14 years, 68% were female, and 45% nonwhite (occlusion sites: internal carotid artery 29%; middle cerebral artery 39%; posterior circulation 32%). Pharmacological or mechanical ERT was initiated beyond 3 hours after symptom onset (median time 4.4 hours) in 61%, 29% had surgery, and 39% were on anticoagulant medication. At discharge, 32% had modified Rankin Scale scores of 0 to 2 (52% discharged home or to rehabilitation facilities); overall mortality was 29%, of which 19% were fatal intracerebral hemorrhages. From the NIS cohort, 477 patients (0.17% of all strokes and 14% of all thrombolysis cases) underwent ERT. Fifteen percent died, and approximately 50% were discharged home or to rehabilitation facilities. Intracerebral hemorrhage occurred in 6%. Fewer good outcomes of the CUMC cohort may be explained by more unfavorable premorbid patient characteristics compared with the NIS cohort.
CONCLUSIONS: Despite significant variability in patient characteristics and treatment methods among 2 sources of data analyzed, ERT in stroke patients not eligible for intravenous thrombolysis appears to be a relatively safe and effective treatment alternative that is being used increasingly nationwide.

Entities:  

Mesh:

Year:  2005        PMID: 16373652     DOI: 10.1161/01.STR.0000198808.90579.65

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus.

Authors:  Wei Zhang; Yong-Sheng Li; Michael A Nardi; Suying Dang; Jing Yang; Yong Ji; Zongdong Li; Simon Karpatkin; Thomas Wisniewski
Journal:  Blood       Date:  2010-06-04       Impact factor: 22.113

2.  Availability of endovascular therapies for cerebrovascular disease at primary stroke centers.

Authors:  Mark J Alberts; Jean Range; William Spencer; Vicki Cantwell; M J Hampel
Journal:  Interv Neuroradiol       Date:  2016-11-30       Impact factor: 1.610

Review 3.  Beyond the time window of intravenous thrombolysis: standing by or by stenting?

Authors:  Xinfeng Liu
Journal:  Interv Neurol       Date:  2012-05

4.  A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke.

Authors:  Ranjana Poddar; Sathyanarayanan Rajagopal; Lucas Winter; Andrea M Allan; Surojit Paul
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-07       Impact factor: 6.200

5.  Selective brain cooling with endovascular intracarotid infusion of cold saline: a pilot feasibility study.

Authors:  J H Choi; R S Marshall; M A Neimark; A A Konstas; E Lin; Y T Chiang; H Mast; T Rundek; J P Mohr; J Pile-Spellman
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-06       Impact factor: 3.825

Review 6.  In cold blood: intraarteral cold infusions for selective brain cooling in stroke.

Authors:  Elga Esposito; Matthias Ebner; Ulf Ziemann; Sven Poli
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

7.  Comparison of short-term outcomes of thrombolysis for in-hospital stroke and out-of-hospital stroke in United States.

Authors:  Yogesh Moradiya; Steven R Levine
Journal:  Stroke       Date:  2013-04-30       Impact factor: 7.914

8.  Dissolution of pre-existing platelet thrombus by synergistic administration of low concentrations of bifunctional antibodies against β3 integrin.

Authors:  Suying Dang; Tao Hong; Thomas Wisniewski; Wei Zhang
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

Review 9.  Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

Authors:  Surojit Paul; Eduardo Candelario-Jalil
Journal:  Exp Neurol       Date:  2020-11-02       Impact factor: 5.330

10.  A thromboembolic model for the efficacy and safety evaluation of combined mechanical and pharmacologic revascularization strategies.

Authors:  Matthew J Gounis; Raul G Nogueira; Manik Mehra; Juyu Chueh; Ajay K Wakhloo
Journal:  J Neurointerv Surg       Date:  2012-09-08       Impact factor: 5.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.